Raymond James Financial Services Advisors Inc. Has $82,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Raymond James Financial Services Advisors Inc. increased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 61.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 48,309 shares of the biotechnology company’s stock after acquiring an additional 18,333 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Heron Therapeutics were worth $82,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Rubric Capital Management LP boosted its position in shares of Heron Therapeutics by 127.3% during the 3rd quarter. Rubric Capital Management LP now owns 26,713,503 shares of the biotechnology company’s stock valued at $27,515,000 after acquiring an additional 14,963,503 shares in the last quarter. JW Asset Management LLC boosted its position in shares of Heron Therapeutics by 9.1% during the 3rd quarter. JW Asset Management LLC now owns 2,407,418 shares of the biotechnology company’s stock valued at $2,480,000 after acquiring an additional 200,000 shares in the last quarter. Tejara Capital Ltd boosted its position in shares of Heron Therapeutics by 28.6% during the 3rd quarter. Tejara Capital Ltd now owns 2,109,681 shares of the biotechnology company’s stock valued at $2,173,000 after acquiring an additional 469,548 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Heron Therapeutics by 100.0% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,000,000 shares of the biotechnology company’s stock valued at $2,060,000 after acquiring an additional 1,000,000 shares in the last quarter. Finally, Monaco Asset Management SAM boosted its position in shares of Heron Therapeutics by 72.1% during the 3rd quarter. Monaco Asset Management SAM now owns 696,908 shares of the biotechnology company’s stock valued at $718,000 after acquiring an additional 291,908 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HRTX has been the subject of several analyst reports. StockNews.com raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Needham & Company LLC reissued a “buy” rating and set a $5.00 price target on shares of Heron Therapeutics in a report on Thursday, April 11th. Finally, Capital One Financial initiated coverage on shares of Heron Therapeutics in a report on Tuesday. They set an “overweight” rating and a $6.00 price target for the company.

Heron Therapeutics Trading Down 3.8 %

Shares of NASDAQ HRTX opened at $2.55 on Friday. Heron Therapeutics, Inc. has a 1-year low of $0.50 and a 1-year high of $3.22. The company has a market cap of $383.34 million, a PE ratio of -2.97 and a beta of 1.68. The company has a 50-day moving average of $2.75 and a two-hundred day moving average of $1.96.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.08. The company had revenue of $34.23 million during the quarter, compared to the consensus estimate of $30.98 million. As a group, equities research analysts forecast that Heron Therapeutics, Inc. will post -0.22 earnings per share for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.